Efficacy in the treatment of depressive disorders

Autores

  • Taysa Leite de Aquino School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Jaiany Rodrigues Liborio School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Ana Luiza Menezes Santana Bezerra School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Giovana Macêdo Egídio Cavalcante School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Dara Fernanda Brito Duarte School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Ana Luíza de Aguiar Rocha Martin School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Juliane dos Anjos de Paula School of Medicine of Juazeiro do Norte – FMJ/Estácio, Juazeiro do Norte, Ceará, Brazil.
  • Modesto Leite Rolim Neto Faculdade de Medicina - Universidade Federal do Cariri - UFCA

DOI:

https://doi.org/10.52329/AvanMed.38

Palavras-chave:

New Treatment, Pharmacological, Depressive Disorder

Resumo

Introduction

Depression, being the most disabling disease in the world and presenting high morbidity and mortality, requires an effective treatment to ensure the maintenance of the patients' quality of life. About a third of patients do not respond adequately to antidepressant treatment. New pharmacological therapies are being approached in order to reduce the unfavorable outcomes resulting from this pathology.

Objective

To develop a systematic review of the literature on the new possibilities of pharmacological treatments for depression in the last four years.

Method

A systematic review was carried out following the PRISMA protocol (Preferred Reporting Items for Systematic Reviews and Meta-Analysis). We have included studies on the effectiveness of new pharmacological therapies in patients with major depressive disorder and treatment-resistant depression.

Results

In the treatment of the major depressive disorder (MDD), the use of brexpiprazole 1 mg/day in addition to the usual antidepressant treatment (ADT) resulted in significant improvement in the main symptoms. Already referring to treatments for treatment-resistant depression (TRD): nasal esketamine proved beneficial in the short term, intravenous (IV) ketamine also appears as an effective therapy.

Conclusion

The use of brexpiprazole 1 mg/day associated with an antidepressant, and the use of lactobacilli represent a new option for those with MDD. In addition, both ketamine, riluzole, and cariprazine appear as new hopes for those who have not yet achieved remission of the depressive disorder with the use of more than two antidepressants

Downloads

Não há dados estatísticos.

Downloads

Publicado

2022-01-22

Como Citar

1.
Aquino TL de, Liborio JR, Bezerra ALMS, Cavalcante GME, Duarte DFB, Martin AL de AR, Paula J dos A de, Rolim Neto ML. Efficacy in the treatment of depressive disorders. am [Internet]. 22º de janeiro de 2022 [citado 28º de novembro de 2022];1(4):138-46. Disponível em: https://www.jornalavancosmedicina.com/index.php/am/article/view/47

Edição

Seção

ARTIGO DE REVISÃO

Artigos mais lidos pelo mesmo(s) autor(es)